Latest Conference Articles

Sleep apnea is a common condition with an impact that goes beyond the affected patient. Diagnosis and treatment need to change to a more patient-centric model in order to improve outcomes and reduce risks.

Less than 40% of patients in a recent study could perform a perfect inhalation with their device. That's a problem for COPD and asthma patients.

An expert delves into the machinations of Type 2 asthma inflammation — a common condition in moderate-to-severe asthma patients.

The Cleveland Clinic's study of CDC-collected data from 1999 to 2015 showed one age group's resilience to asthma mortality.

While advanced therapies approved for either should be considered for ACO patients, there hasn't be sole investigations.

A recent survey found that 85% of commercial drivers tested for the sleeping condition tested positive for it.

It's normal to find misleading videos online, but scientists have found that even the ones published by health systems aren't up to snuff.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Alpha-1 Antitrypsin Deficiency is often diagnosed long after it's developed, and late diagnosis leads to worse outcomes.

A Florida questionnaire showed that only one-third of patients’ family members were satisfied with their level of knowledge.

Nitrogen dioxide, particulate matter, elemental carbon, and winter average sulfur dioxide were more prevalent in high asthma prevalence neighborhoods.

Despite medical cannabis being legalized in 28 states, a majority of future internists expressed concern for their limited knowledge.

Bruce Cree, MD, PhD, spoke about the connection between brain volume loss and disability progression in patients with MS in the long term.

Ibudilast slowed the rate of brain atrophy by 48% without inducing significant toxicity for progressive MS.

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.

The TOPIC study results additionally showed a strong association between CGMV loss and CDMS conversion.

Aaron Boster, MD, spoke about the efforts and his involvement in the MS Paths program.

Tanuja Chitnis, MD, spoke about the first-of-its-kind PARADIGMS trial, and pediatric multiple sclerosis, as well as how it differs from the condition in adults.

The PARADIGMS data showed an 81.9% reduction in the rate of annualized relapses.

Ozanimod reduced the annualized relapse rate and lowered the number of T2 lesions versus interferon beta-1a for RMS.

Ozanimod reduced ARR and showed marked reductions in T2 lesions compared with interferon β-1a for RMS.

Subgroup analysis revealed a greater improvement for patients with baseline visual impairment.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Francisco Quintana, MD, spoke about his efforts to identify new drugs for treating multiple sclerosis and how reliable biomarkers are the biggest need in treating MS.

Nearly all patients with relapsing multiple sclerosis treated with ublituximab remained relapsed free after 24 weeks.

Ruth Ann Marrie, MD, PhD, FRCP, spoke about the prevalence of comorbidities in patients with MS, and how these patients are often overlooked and left out of clinical trials.

Martin Weber, MD, spoke about the role that B cells and antibodies play in the treatment of multiple sclerosis.

MD1003 led to a pseudo-atrophy phenomenon that was likely related to remyelination.

The EXPAND trial results supported the potential neuroprotective effects of siponimod.

Infections in immunocompromised patients continue to rise because of more enhanced diagnostics and increased cultures.